相关实验视频

Updated: Jun 4, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.0K

克服安德森-法布里病的抗性:当前的治疗挑战和未来的前景

Maria Cristina Carella1, Cinzia Forleo1, Pierpaolo Caretto1

  • 1Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Polyclinic University Hospital, 70124 Bari, Italy.

Journal of clinical medicine
|December 17, 2024
PubMed
概括

安德森-法布里病 (AFD) 由于耐药性机制,提出了治疗挑战. 像mRNA和基因疗法这样的新兴疗法为有效的安德森-法布里病管理提供了新的希望.

关键词:
安德森法布里病的疾病.对抗药物抗体的抗体.陪伴者治疗是一种陪伴疗法.酶替代疗法 酶替代疗法基因疗法 基因疗法它们是mRNARNA.电阻机制的阻力机制.量身定制的治疗方法

更多相关视频

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.2K

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516